BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report-Reference-Cited by-同舟云学术

BRAF V600E-mutated Colorectal Neuroendocrine Carcinoma Effectively Treated with a Chemotherapy Protocol for BRAF-mutated Metastatic Colorectal Cancer: A Case Report

Published:2024 Issue: Volume: Page:
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Owaki Seira¹,Mori Yoshinori¹,Nakai Shunsuke¹,Maeda Hideki¹,Imazu Mitsuki¹,Tomita Yusaku¹,Kanaiwa Hiroki¹,Yamaguchi Ayana¹,Kitagawa Mika¹,Hirano Atsuyuki¹,Kimura Yoshihide¹,Tsuchida Kenji¹,Kataoka Hiromi²

Affiliation:

1. Department of Gastroenterology, Nagoya City University West Medical Center, Japan

2. Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_2870-23/_pdf

Reference21 articles.

1. 1. Bernick PE, Klimstra DS, Shia J, et al. Neuroendocrine carcinomas of the colon and rectum. Dis Colon Rectum 47: 163-169, 2004.

2. 2. Conte B, George B, Overman M, et al. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer 15: e1-e7, 2016.

3. 3. Shen C, Tannenbaum D, Horn R, et al. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review. JAMA Netw Open 5: e2213588, 2022.

4. 4. Morizane C, Machida N, Honma Y, et al. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol 8: 1447-1455, 2022.

5. 5. Burkart J, Owen D, Shah MH, et al. Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon. J Natl Compr Canc Netw 16: 1035-1040, 2018.